An Open Label Study to Assess the Safety and Efficacy of COR-003(2S 4R-Ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Site Image

Study Overview

The purpose of this clinical research study is to find out if the drug COR-003 is safe and has beneficial effects in patients who have Cushings disease and to determine the most effective dosage for each individual subject. . COR-003 is taken in pill form twice a day. The study will involve 90 people with Cushings disease in North America and in certain European countries. The study will begin with a screening period followed by a dose finding phase, lasting 2-16 weeks, to determine the most effective and tolerable maximum dose for an individual subject. Once the appropriate dose has been determined, subjects will take the study medicine for 6 months. At the end of six months, subjects will be followed for another 6 months so that more information can be collected.

  • Study Identifier: 819642

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email psom-ocr@pobox.upenn.edu